AEterna Zentaris - 48 Year Dividend History | AEZS

Historical dividend payout and yield for AEterna Zentaris (AEZS) since 1971. The current TTM dividend payout for AEterna Zentaris (AEZS) as of September 20, 2019 is $0.00. The current dividend yield for AEterna Zentaris as of September 20, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.027B $0.027B
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Stock Name Country Market Cap PE Ratio